IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 20,000 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 20,000 shares of the business’s stock in a transaction dated Thursday, May 8th. The shares were purchased at an average price of $1.15 per share, with a total value of $23,000.00. Following the acquisition, the insider directly owned 197,497 shares in the company, valued at approximately $227,121.55. The trade was a 11.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Performance

IRIX stock opened at $0.88 on Thursday. The firm has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. The firm’s 50 day moving average price is $0.73 and its 200-day moving average price is $0.95. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. Equities research analysts predict that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, IRIDEX has a consensus rating of “Hold” and a consensus price target of $3.00.

Hedge Funds Weigh In On IRIDEX

Institutional investors have recently bought and sold shares of the company. United Capital Financial Advisors LLC purchased a new stake in IRIDEX during the second quarter worth about $41,000. Weber Capital Management LLC ADV acquired a new stake in shares of IRIDEX during the second quarter worth about $206,616. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX in the second quarter valued at approximately $30,000. Bank of New York Mellon Corp acquired a new position in shares of IRIDEX in the second quarter valued at approximately $29,000. Finally, Renaissance Technologies LLC grew its holdings in shares of IRIDEX by 6.7% in the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 25,067 shares in the last quarter. 20.10% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.